EP Patent

EP0825885B1 — Pulmonary delivery of aerosolized medicaments

Assigned to Novartis Pharma AG · Expires 2004-03-17 · 22y expired

What this patent protects

The invention provides a spray-dried pharmaceutical-based dispersible dry powder composition for pulmonary delivery, comprising: a therapeutically effective amount of a macromolecule; and a pharmaceutically acceptable carrier with the provisos that: (i) the carrier is neither hyd…

USPTO Abstract

The invention provides a spray-dried pharmaceutical-based dispersible dry powder composition for pulmonary delivery, comprising: a therapeutically effective amount of a macromolecule; and a pharmaceutically acceptable carrier with the provisos that: (i) the carrier is neither hydroxypropylcellulose or hydroxypropylmethylcellulose; and (ii) the macromolecule is neither insulin nor an interferon.

Drugs covered by this patent

Patent Metadata

Patent number
EP0825885B1
Jurisdiction
EP
Classification
—
Expires
2004-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.